Background:A two-compound product containing calcipotriol and betamethasone dipropionate (Daivobet./Dovobet.) has been evaluated in a large clinical trial programme, providing a wealth of data on the treatment of psor...Background:A two-compound product containing calcipotriol and betamethasone dipropionate (Daivobet./Dovobet.) has been evaluated in a large clinical trial programme, providing a wealth of data on the treatment of psoriasis vulgaris. Objective:To determine the effectiveness of the two-compound product in patients with mild, moderate and severe psoriasis vulgaris. Methods:Data from over 1,534 patients with psoriasis vulgaris who received the two-compound product once daily for at least 4 weeks in four randomised, double-blind studies were pooled. A meta-analysis of the pooled data is presented. Severity of psoriasis at baseline was determined by investigator assessment and Psoriasis Area and Severity Index (PASI) score. Results:For patients with severe disease defined by PASI score (PASI baseline ≥17), the mean reduction in PASI after up to 4 weeks of treatment was 71.6%compared with 68.9 and 67.2%for those with moderate (PASI baseline 5.1-16.0) and mild disease (PASI baseline ≤5). Corresponding reductions for investigator-assessed severity were 72.6, 69.1 and 68.7%, respectively. Conclusion:Although the metaanalysis of the data from these four studies was performed post hoc, we may conclude that the two-compound product provided highly effective treatment of psoriasis,regardless of the category of baseline disease severity.展开更多
文摘Background:A two-compound product containing calcipotriol and betamethasone dipropionate (Daivobet./Dovobet.) has been evaluated in a large clinical trial programme, providing a wealth of data on the treatment of psoriasis vulgaris. Objective:To determine the effectiveness of the two-compound product in patients with mild, moderate and severe psoriasis vulgaris. Methods:Data from over 1,534 patients with psoriasis vulgaris who received the two-compound product once daily for at least 4 weeks in four randomised, double-blind studies were pooled. A meta-analysis of the pooled data is presented. Severity of psoriasis at baseline was determined by investigator assessment and Psoriasis Area and Severity Index (PASI) score. Results:For patients with severe disease defined by PASI score (PASI baseline ≥17), the mean reduction in PASI after up to 4 weeks of treatment was 71.6%compared with 68.9 and 67.2%for those with moderate (PASI baseline 5.1-16.0) and mild disease (PASI baseline ≤5). Corresponding reductions for investigator-assessed severity were 72.6, 69.1 and 68.7%, respectively. Conclusion:Although the metaanalysis of the data from these four studies was performed post hoc, we may conclude that the two-compound product provided highly effective treatment of psoriasis,regardless of the category of baseline disease severity.
